The Novo Nordisk-funded FLOW trial, published in the New England Journal of Medicine on 24 May 2024, randomly assigned patients with T2DM and CKD to receive subcutaneous semaglutide at a dose of 1.0mg weekly, or a placebo, to test whether treatment with semaglutide would mitigate the high risk for kidney failure, cardiovascular events and death
If the itching is persistent, severe, or accompanied by other symptoms such as swelling, redness, or difficulty breathing, it is essential to contact a healthcare provider immediately
Gut health applications can show results faster
It supports broader treatment plans and may not replace CPAP for all patients, particularly those with central sleep apnea or other complicating factors
Anabolic agents
One capsule a day, every day